Flushing and the HDL-C response to extended-release niacin

Journal of Clinical Lipidology

Volumn 2, Issue 4, 2008, Pages 285-288

  Taylor, Allen J ^a   Stanek, Eric J ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Clinical trials; Imaging studies; Size: small (<200 individuals); Type: lipoprotein modifying

Indexed keywords

ACETYLSALICYLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DELAYED RELEASE FORMULATION; DIABETES MELLITUS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FLUSHING; GENDER; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SELF REPORT; SIDE EFFECT; TREATMENT DURATION;

EID: 48549100919     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.05.002     Document Type: Article

References (15)

1. Benyó Z., Gille A., Kero J., et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 115 (2005) 3634-3640
2. Capuzzi D.M., Guyton J.R., Morgan J.M., et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 17 suppl 12A (1998) 82 74U-81U
3. The Coronary Drug Project. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
4. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
5. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
6. Taylor A.J., Lee H.J., and Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 22 (2006) 2243-2250
7. Rubic T., Trottmann M., and Lorenz R.L. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 67 (2004) 411-419
8. Jin W., Millar J.S., Broedl U., Glick J.M., and Rader D.J. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest 111 (2003) 357-362
9. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 89 (1994) 1333-1445
10. Yancey P.G., Kawashiri M.A., Moore R., et al. In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux. J Lipid Res 45 (2004) 337-346
11. Navab M., Hama S., Hough G., and Fogelman A.M. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice. Circulation 108 (2003) 1735-1739
12. Benyo Z., Gille A., Bennett C.L., Clausen B.E., and Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharmacol 70 (2006) 1844-1849
13. Horrobin D.F. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fatty Acids 55 (1996) 3-7
14. Messamore E., Hoffman W.F., and Janowsky A. The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study. Schizophr Res 62 (2003) 251-258
15. Knopp R.H., Alagona P., Davidson M., et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 47 (1998) 1097-1104